DCGI: 2 indigenous vaccines gets nod to start human trials

The Drug Controller General of India has granted nod to two indigenous candidate vaccines for Covid-19 for the commencement of early phase human trials in the country, said the Indian Council of Medical Research (ICMR).

Dr Balram Bhargava said that, “There are two Indian indigenous candidate vaccines. They have undergone successful toxicity studies in rats, mice and rabbits. The data was submitted to DCGI following which both these got clearance to start early phase human trials early this month. They have got their sites ready and they are doing their clinical study on approximately a thousand volunteers each at different sites,”

“The experiments for the two vaccines, among others, are also being done at NIV, Pune and spoke about the various programmes being carried out to develop a vaccine globally. Recently, Russia has fast-tracked a vaccine which has been successful in the early phases and they have fast-tracked its development. The whole world has applauded it and congratulated Russia. China has also fast-tracked its vaccine programme and fast-tracked its studies with vaccines. The US has again fast-tracked two of its vaccine candidates and the UK is also looking at how it can fastrack the Oxford vaccine candidate. Any vaccine produced in any party part of the world will ultimately have to be scaled up by India or by China. Because these are the two major vaccine producers of the world. Everyone who is trying to prepare a vaccine is in talks with India”, Bhargava added.

  • Related Posts

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

    BMJ Research Forum all set to mull over in Delhi on September 5 New Delhi: Research in healthcare in India is a dime a dozen. But the real question that…

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Dr Rajendra Pratap Gupta gets nominated to advise UN Secretary General Geneva/ New Delhi: Former advisor to Union Health Minister of India JP Nadda in his earlier stint and a…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Puresta launches EVERQ, AI-powered skin-health platform

    Puresta launches EVERQ, AI-powered skin-health platform

    Stem cell therapy for autism only in approved clinical trials: Centre

    Stem cell therapy for autism only in approved clinical trials: Centre